As our knowledge of the genetics of disease increases, we're recognizing that new therapeutic modalities are required to treat and ultimately cure diseases. Although regulatory approvals seem to indicate a lag in innovation, they represent an important proof of principle that the technical, regulatory, and commercial hurdles can be cleared for new modalities. This event will provide an overview of some of the exciting developments in this area. (View the event in your time zone.)
Agenda
Moderator: Andrew Coles, PhD (AbbVie)
1:05 - 1:35 p.m.
Sarah Glass, PhD (n-Lorem Foundation)
The future for N-1 therapies
1:35 - 2:05 p.m.
Anastasia Khvorova, PhD (UMass Chan Medical School)
New developments in the treatment of Huntington’s disease
2:05 - 2:35 p.m.
Paloma Giangrande, PhD (Wave Life Sciences)
RNA editing as a therapeutic modality
2:35 - 3 p.m.
Panel discussion